Koh Bong Y's Form 4 filing
KalVista Pharmaceuticals, Inc. (KALV) · filed Mar 27, 2026
- Accession no.
- 0001231919-26-000286
- Filed
- Mar 27, 2026, 5:50 PM ET
- Trade date
- Mar 25-26, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $3.69M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Koh Bong YCIK 0001615979 | 10% Owner |
| Shah Nimish PCIK 0001698082 | 10% Owner |
| Venrock Healthcare Capital Partners III, L.P.CIK 0001738048 | 10% Owner |
| VHCP Management III, LLCCIK 0001738053 | 10% Owner |
| VHCP Co-Investment Holdings III, LLCCIK 0001750761 | 10% Owner |
| Venrock Healthcare Capital Partners EG, L.P.CIK 0001808512 | 10% Owner |
| VHCP Management EG, LLCCIK 0001808518 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Stock | SSaleDisposed | −174,485 | $16.95F1 | −$2,957,520.75 | 5,129,500 | Indirect | |
| Mar 25, 2026 | Common Stock | SSaleDisposed | −160 | $17.53F4 | −$2,804.8 | 5,129,340 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −21,386 | $17.76F6 | −$379,815.36 | 5,107,954 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −15,417 | $18.82F8 | −$290,147.94 | 5,092,537 | Indirect | |
| Mar 26, 2026 | Common Stock | SSaleDisposed | −3,183 | $19.12F10 | −$60,858.96 | 5,089,354 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $16.51 to $17.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.51 to $17.55 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $17.07 to $18.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F8
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $18.07 to $19.06 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F10
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $19.07 to $19.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.